These TNF-α inhibitors (TNFis) have been approved by the Food and Drug Administration for the treatment of RA, Crohn’s disease, psoriasis, ankylosing spondylitis, etc. The annual global sales of TNFis have exceeded tens of billions of dollars, becoming one of the world’s best-selling drugs. The gene discussed is TNF; the disease is psoriasis.